Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (<scp>W</scp>est <scp>J</scp>apan <scp>O</scp>ncology <scp>G</scp>roup 5910L): An open‐label, randomized, phase 2 trial
Masayuki Takeda(Kindai University), Isamu Okamoto(Kyushu University Hospital), Haruyasu Murakami(Shizuoka Cancer Center), Haruhiro Saito(Kanagawa Cancer Center), Hidetoshi Hayashi(Kindai University), Kimio Yonesaka(Kindai University), Naoyuki Nogami(Hospital Universitario Insular de Gran Canaria), Koichi Azuma(Kyushu University Hospital), Akihito Kubo(Aichi Medical University), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Toshiyuki Sawa(Kite (United States)), Haruko Daga(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Yoshiko Urata(Miyoshi Kasei (Japan)), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Tomonori Hirashima(Osaka Prefectural Medical Center), Morihito Okada(Hiroshima University), Yoichi Nakanishi(RIKEN Center for Integrative Medical Sciences), Eiji Miyahara(Hiroshima University), Takeharu Yamanaka(National Cancer Center Hospital East)
Cited by 42
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k